Enzalutamide for treating non-metastatic hormone-relapsed prostate cancer (Single Technology Assessment)
As part of the NICE single technology appraisal process, the Aberdeen Evidence Review Group (ERG) was invited to critically review the company’s submission related to the clinical and cost-effectiveness Enzalutamide for treating non-metastatic hormone-relapsed prostate cancer.
Outcome and Translation
Following consideration of evidence submitted by the company, and a review of the submission submitted by the evidence review group, NICE decided not to recommend Enzalutamide for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults. Details of the appraisal and the full guidance are available on the NICE website: Enzalutamide for hormone-relapsed non-metastatic prostate cancer. Technology appraisal guidance [TA580].
External collaborators: C., Ramsay, M. Brazzelli, and M. Campbell (Health Services Research Unit, (HSRU), University of Aberdeen
Robertson, C., Chong, H., Scotland, G., Cooper, D., Ramsay, C., Urquhart, G. and Aucott, L. (2018) Enzalutamide for treating non-metastatic hormone-relapsed prostate cancer, (NICE Technology Appraisal Guidance - TA580), Aberdeen Health Technology Assessment Group.